EVO Earnings Prediction
The chart below shows how EVO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, EVO sees a +0.00% change in stock price 10 days leading up to the earnings, and a +0.00% change 10 days following the report. On the earnings day itself, the stock moves by +0.00%. This data can give you a slight idea of what to expect for the next quarter's release.
EVO Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
--
--
--
No Data Available
EVO Earnings Analysis
Evotec SE American Depositary Shares Corporation (EVO.O) Earnings Conference Call
Positive
Stable Revenue Performance: Revenues for the nine-month period reached €575.7 million, in line with the same period in 2023, driven by two counterbalanced trends.
Revenue Growth Surge: Just-Evotec Biologics continues to grow with €128.7 million revenue versus €74.1 million in the prior year, representing a 74% increase.
Manufacturing Plant Operational Timeline: The new manufacturing plant in Toulouse, France, is expected to be fully operational in Q1 2025, as planned.
Positive Cash Flow Improvement: Cash flow has seen a positive turn in Q3 with a positive free cash flow of €16.7 million compared to a negative €80 million in Q1 and Q2.
Revenue Forecast 2024: Overall, the company expects group revenues for the full year 2024 to land between €790 million and €820 million.
Negative
R&D Revenue Decline: On shared R&D revenue has declined from €506.1 million last year September to €447 million this year, due to a persistent soft market.
Negative Adjusted EBITDA: Adjusted group EBITDA for nine months 2024 reached minus €6 million due to losses in shared R&D of €6.8 million based on soft revenues and a high fixed cost base.
R&D Spending Reduction: Our R&D spending has reduced by 15% versus prior year from €48.4 million in H1 2023, €41.1 million in H1 2024, as we focus on platforms that are most relevant for our partners.
Challenging Market Conditions: We face a challenging nine months driven by our fixed cost base in combination with the slow market demand for our shared R&D segment.
Core Operations Profitability: Overall, our core operations are profitable with an adjusted EBITDA of €0.8 million.
EVO FAQs
How does EVO typically perform around its earnings report dates?
Is Evotec SE (EVO) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
EVO Earning Call Sentiment
Evotec SE (EVO) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
EVO.O
-0.82%Positive
The earnings call summary presents a mixed picture: while there are positive elements like improved gross margin and liquidity, along with optimistic guidance, there are also concerns over liquidity risks, workforce reductions, and dependency on partnerships. The Q&A reveals management's confidence in meeting guidance, yet lacks clarity on certain financial metrics. The absence of a share buyback or dividend program further tempers optimism. Given the company's market cap, these factors suggest a neutral stock price movement in the short term.
